A.R.T. Advisors’s Moleculin Biotech MBRX Stock Holding History

A.R.T. Advisors’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-13	Closed	-$31K	–	1561
2019 Q3	$31K	Buy	+13	New	+$33.6K	﹤0.01%	1351

Other funds holding MBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WIC

Whitegate Investment Counselors Concord, New Hampshire $315M AUM 10.6% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

A.R.T. Advisors's MBRX Position: Q4 2019 in Review

A.R.T. Advisors sold out of Moleculin Biotech (MBRX) in Q4 2019, closing a stake of 13 shares — an estimated $31K sold.

A.R.T. Advisors first reported a position in MBRX in Q3 2019 and held it in 1 quarter. The position peaked at $31K in Q3 2019. 22 funds tracked by Wall St. Rank hold MBRX as of Q4 2019.

A.R.T. Advisors reported no remaining Moleculin Biotech position as of Q4 2019 after selling out during the quarter.
A.R.T. Advisors sold 13 Moleculin Biotech shares in Q4 2019, an estimated $31K.
A.R.T. Advisors first reported a position in Moleculin Biotech in Q3 2019 and held it in 1 quarter.
A.R.T. Advisors's Moleculin Biotech position peaked at $31K in Q3 2019.
22 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.